Logo

Flare Therapeutics Inks Pact with Roche to Develop Small Molecules Targeting Undrugged Transcription Factors in Oncology

Share this
Roche & Flare Therapeutics

Flare Therapeutics Inks Pact with Roche to Develop Small Molecules Targeting Undrugged Transcription Factors in Oncology

Shots:

  • The alliance will discover small molecule therapeutics targeting undrugged transcription factors in oncology, using Flare’s proteomic & mass spectrometry platform as well as electrophilic compounds library
  • Flare will lead discovery & preclinical work plus is entitled to get $70M upfront in cash, >$1.8B discovery, development & commercialization milestones along with royalties, while Roche will handle further development & commercialization
  • Flare keeps the right to co-fund the development of one target in exchange for higher US royalties. It also retains ownership of its pipeline, incl. FX-909 for advanced urothelial cancer (entering IND-enabling trials) as well as other oncology & therapeutic programs

Ref: Flare Therapeutics | Image: Roche & Flare Therapeutics 

Related News:- Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions